From the Research
Intraperitoneal opioid (IPOS) therapy has not been directly mentioned in the provided studies, however, the use of intraperitoneal administration of oxaliplatin has been explored in research involving non-palliative patients with peritoneal metastases. The most recent and highest quality study, 1, investigated the systemic pharmacokinetics of oxaliplatin after intraperitoneal administration by electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC) in patients with unresectable colorectal peritoneal metastases.
- Key findings from this study include:
- The plasma ultrafiltrate Cmax of oxaliplatin reached 1.36-1.90 µg/mL after 30 min with an AUC0-24 h of 9.6-11.7 µg/mL * h.
- The plasma Cmax reached 2.67-3.28 µg/mL after 90 min with an AUC0-24 h of 49.0-59.5 µg/mL * h.
- The absorption rate constant (Ka) was 1.13/h.
- Other studies, such as 2 and 3, have also explored the use of ePIPAC with oxaliplatin in patients with peritoneal metastases, demonstrating its safety and feasibility.
- The use of intraperitoneal administration of oxaliplatin in non-palliative patients with peritoneal metastases is a promising area of research, with potential benefits in terms of tumor response and survival. However, further studies are needed to fully understand its efficacy and role in the treatment of peritoneal metastases.
- It is essential to note that the provided studies do not directly address the use of intraperitoneal opioid (IPOS) therapy, but rather focus on the administration of oxaliplatin via ePIPAC.
- In the context of real-life clinical medicine, the use of ePIPAC with oxaliplatin may be considered a viable option for patients with unresectable peritoneal metastases, particularly those with colorectal cancer. However, this should be done under the guidance of a qualified healthcare professional and with careful consideration of the potential risks and benefits.